News >

Venetoclax Spearheads Myriad of AML Advances

Kristi Rosa
Published: Wednesday, May 01, 2019

Jacqueline S. Garcia, MD

Jacqueline S. Garcia, MD

One of the most exciting advances made in the acute myeloid leukemia (AML) paradigm has been the addition of venetoclax (Venclexta), said Jacqueline S. Garcia, MD, as the agent has been shown to have high response rates with durable remissions.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication